ライフサイエンスコーパス: per day

1 ncow milk consumption (number of 250-mL cups per day).

2 0 mg/kg per day), and group D (Val, 30 mg/kg per day).

3 e hydrochloride at a dosage of 1.5 to 3.0 mg per day.

4 reducing the tacrolimus dose to 14 mg twice per day.

5 filing, the RP2D was defined as 800 mg twice per day.

6 te days with or without vigabatrin 100 mg/kg per day.

7 terms of mean ethanol consumption (in grams) per day.

8 200 mg, and tenofovir alafenamide 10 mg once per day.

9 CI, 0.53-0.78) per 1 million persons at risk per day.

10 smoker consuming 10 conventional cigarettes per day.

11 th a CO2 point source emitting 41.6 kilotons per day.

12 nd legume intake was 3.91 (SD 2.77) servings per day.

13 3 design and expansion at 40, 80, and 100 mg per day.

14 to increase habitual water intake to 8 cups per day.

15 t reached at doses ranging from 50 to 650 mg per day.

16 of 5 mg/kg isoniazid and 10 mg/kg rifampicin per day.

17 .3 mug/m(3) over 20 days of exposure for 5 h per day.

18 cents achieved the target of 8 cups of water per day.

19 stepwise dose ramp-up over 5 weeks to 400 mg per day.

20 eloped enabling measurement of up to 18 pots per day.

21 were unaware of their HCV infection was 2.5 per day.

22 egardless of their awareness status) was 0.7 per day.

23 ho reported drinking 4 cups or less of water per day.

24 zeolites with rates as low as few nanometers per day.

25 es county, reaching about 83 million gallons per day.

26 se range from 1.5 to 2.0mg/kg of body weight per day.

27 , and longer index CRT episodes (adjusted HR per day 0.996, 0.994-0.998 in Camden and Islington; 0.98

28 tality was lowest for three to four servings per day (0.78, 95% CI 0.69-0.88) compared with the refer

29 th children's BMI </=6 y of age [per serving per day: 0.04 SD score (SDS); 95% CI: 0.00, 0.07 SDS].

30 [per risk allele for each soft drink serving per day: 0.05 cm/y (95% CI: 0.02, 0.09 cm/y; P = 0.001)

31 ing BMIZ (adjusted beta per serving increase per day: 0.09; 95% CI: 0.02, 0.15) and risk of overweigh

32 ocaine using an extended-access regimen (6 h per day, 10 days); controls self-administered saline.

33 east-Asian heritage) to a maximum of 300 mg per day (150 mg per day for patients of east-Asian herit

34 157) in the CGM plus CSII group and 741 min per day (225) in the CGM plus MDI group (adjusted mean t

35 ay than those who saw fewer than 25 patients per day (3.1 percentage points [CI, 2.1 to 4.0 percentag

36 ed with four cycles of sunitinib (50 mg once per day, 4 weeks of receiving treatment followed by 2 we

37 60 mg once per day) or sunitinib (50 mg once per day; 4 weeks on, 2 weeks off).

38 ce were exposed to the smoke of 5 cigarettes per day, 5 days a week, for 8 weeks, in a ventilated smo

39 d initiated eltrombopag or placebo at 100 mg per day (50 mg per day for patients of east-Asian herita

40 rage reduction in energy intake of 38.4 kcal per day (95% CI 36.3-40.7) by the end of the fifth year.

41 ol group (difference from baseline, 1.2 cups per day [95% CI, 0.2 to 2.2]; P = .02) (difference betwe

42 = .02) (difference between groups, 1.6 cups per day [95% CI, 0.2 to 3.0 cups per day]; P = .03).

43 er group (difference from baseline, 2.8 cups per day [95% CI, 1.8 to 3.8]; P < .001) compared with th

44 e was evaluated at 63% of the ascorbate pool per day, a percentage that was constant and independent

45 s of adjunctive rifampicin (600 mg or 900 mg per day according to weight, oral or intravenous) versus

46 gs per capita range from 1.8 to 15.4 gallons per day across 18 counties examined.

47 per day, escalated to three capsules (15 mg) per day after 3 months.

48 ociated with heavy smoking (>/=30 cigarettes per day) among daily smokers (OR = 1.08; 95%CI = 1.02-1.

49 We use three poverty lines: the US$1.90 per day and $3.10 per day international poverty lines an

50 Larger lorcaserin (1.0 mg/kg per day and 0.1 mg/kg/h) and pimavanserin (10 mg/kg per

51 ions between changes in ADAU or hours active per day and changes in standard functional assessments (

52 Associations between hours active per day and clinical characteristics were similar.

53 ts share association signals with cigarettes per day and former smoking, substantially greater than r

54 Compared with the referent (<4 h of sitting per day and highest quartile of physical activity [>35.5

55 Patients received oral erlotinib 150 mg per day and intravenous bevacizumab 15 mg/kg every 21 da

56 r day poverty line but positive at the $3.10 per day and relative poverty lines.

57 re added sugars in terms of per capita grams per day and the percentage of calories from packaged bev

58 r approximately 6 teaspoons) of added sugars per day and to avoid added sugars for children <2 years

59 he association between protein intake (grams per day) and BMD, ALM, appendicular lean mass normalized

60 ycles of intravenous fludarabine (25 mg/m(2) per day) and cyclophosphamide (250 mg/m(2) per day) for

61 easures: Adherence to glasses wearing (hours per day) and effect on VA.

62 whereas low alcohol consumption (0.01-2.5 g per day) and high BMI had a protective effect.

63 tration of ineffective lorcaserin (0.1 mg/kg per day) and pimavanserin (0.32 mg/kg per day) doses als

64 outcomes across quartiles of protein (grams per day) and protein food clusters.The mean +/- SD age o

65 er day)/mycophenolate mofetil (MMF, 60 mg/kg per day), and anti-CD3 (50 mug/day) either alone or in c

66 per day), group C (CsA + Val, 30 + 30 mg/kg per day), and group D (Val, 30 mg/kg per day).

67 ight per day), topiramate (2 mg per kilogram per day), and placebo in children and adolescents 8 to 1

68 DSM criteria), smoking 10 or more cigarettes per day, and a willingness to attempt smoking cessation.

69 insulin requirement was 0.38 (0.04-0.5) U/kg per day, and median HbA1c was 6.6% (5.9%-8.1%).

70 oms with daily smoking, number of cigarettes per day, and nicotine dependence was greater in females

71 es smoked per day, number of vaping episodes per day, and number of puffs per vaping episode) at the

72 a low self-discharge constant of just 0.0012 per day, and stable poststorage cyclability after storin

73 direction at a rate of one to two kilometres per day, and that it is caused either by episodic erupti

74 aware of their HIV infection was 0.5 persons per day, and the detection rate of HIV-infected persons

75 randomly assigned to celecoxib (400 mg twice per day; arm A) or placebo (arm B).

76 eased water consumption, typically to 8 cups per day, as part of a weight-reducing diet.

77 The mean numbers of cigarettes smoked per day at 2 weeks and 1-month were significantly lower

78 dose in responders decreased from 0.29 mg/kg per day at baseline to 0.12 mg/kg per day at week 49; 5

79 orted drinking approximately 2 cups of water per day at baseline.

80 d with a greater number of cigarettes smoked per day at follow-up (adjusted rate ratio [RR], 7.03; 95

81 0.29 mg/kg per day at baseline to 0.12 mg/kg per day at week 49; 5 responders discontinued corticoste

82 o puffs twice per day, equivalent to 800 mug per day beclomethasone dipropionate) or placebo.

83 and reduced the number of cigarettes smoked per day by participants 1 month after treatment relative

84 ed an accelerated dosing schedule (to 400 mg per day by week 3).

85 adenomas in the rectum only (multiple times per day compared with <1 time/wk, PR: 1.87; 95% CI: 1.19

86 ical functioning and lower PA (average steps per day) compared to IBD-RE and HC.

87 nse to low dose of angiotensin II (0.3 mg/kg per day) compared with wild-type C57Bl/6J mice.

88 ient self-reported, estimates of steps taken per day correlated with smartphone data (surrogates: n =

89 ed by a step count difference of 1,742 steps per day ( d = -0.43; P < .01); however, on average, the

90 damustine monotherapy dosing was 120 mg/m(2) per day (days 1 and 2, all cycles).

91 1, cycles 2-6) plus bendamustine 90 mg/m(2) per day (days 1 and 2, cycles 1-6), and bendamustine mon

92 th either ipatasertib 400 mg or placebo once per day (days 1-21) every 28 days until disease progress

93 ents (N = 135) experiencing four or more BMs per day despite stable-dose somatostatin analog therapy

94 plementation at a dose of 60 mg per kilogram per day did not result in a lower risk of physiological

95 , as fluoxetine is prescribed as one capsule per day, disposal is unlikely to be at the patient level

96 PT2385 was administered orally at twice-per-day doses of 100 to 1,800 mg, according to a 3 + 3 d

97 mg/kg per day) and pimavanserin (0.32 mg/kg per day) doses also failed to significantly alter cocain

98 and 0.1 mg/kg/h) and pimavanserin (10 mg/kg per day) doses primarily decreased rates of operant beha

99 Oxygenic photosynthesis was limited to 4 h per day, due to sulfide inhibition in the early morning

100 orted a reduction in mean time in pain (TIP) per day during the 15-day maintenance period, from 424 m

101 With topical steroid therapy 5 times per day during the first postoperative week, we observed

102 Patient 2 reported a reduction in mean TIP per day during the maintenance period, from 61 minutes w

103 prednisolone or prednisone of 4.0 mg or less per day during weeks 48 through 52 (odds ratio, 0.20; 95

104 nd total mortality at three to four servings per day (equivalent to 375-500 g/day).

105 orticosteroids (QVAR 80 mug, two puffs twice per day, equivalent to 800 mug per day beclomethasone di

106 The starting dose was two capsules (10 mg) per day, escalated to three capsules (15 mg) per day aft

107 rigidity, return) of greater than 1.5 hours per day (excluding morning akinesia).

108 f brain metastases) to oral ceritinib 750 mg per day fasted (in 21 day treatment cycles) or chemother

109 g hydroxyurea to placebo at 20 +/- 2.5 mg/kg per day for 12 months.

110 elbasvir 50 mg plus grazoprevir 100 mg once per day for 12 weeks (immediate treatment group) or plac

111 elbasvir 50 mg plus grazoprevir 100 mg once per day for 12 weeks beginning at week 16 (deferred trea

112 5 mg/kg isoniazid and 25 mg/kg pyrazinamide per day for 12 weeks, followed by 14 weeks of 5 mg/kg is

113 to treatment group A (150 mg oral vismodegib per day for 12 weeks, then three rounds of 8 weeks of pl

114 er day for 4 days) and melphalan (60 mg/m(2) per day for 2 days).

115 of 850 cGy plus cyclophosphamide of 60 mg/kg per day for 2 days).

116 day for 5 days, cyclophosphamide of 60 mg/kg per day for 2 days, and total body irradiation (TBI).

117 was followed by eye drops instilled 4 times per day for 21 days with placebo, placebo, or dexamethas

118 patients were given oral lenalidomide 25 mg per day for 21 of 28 days until lymphoma progression or

119 or treatment group B (150 mg oral vismodegib per day for 24 weeks, then three rounds of 8 weeks of pl

120 s were permitted to sleep for up to 14 hours per day for 28 days.

121 ce per day for 7 days, followed by 0.5 mg/kg per day for 3 days).

122 capsules (221 patients), at a dose of 600 mg per day for 3 days, followed by 400 mg per day, for 11 d

123 per day for 4 days, and melphalan 70 mg/m(2) per day for 3 days, with doses for all three drugs modif

124 to blast wave pressure of 300 kPa (43.5 psi) per day for 3 successive days, and euthanized 30 days af

125 Escitalopram was given at a dose of 10 mg per day for 3 weeks and 20 mg per day thereafter.

126 he patient had smoked one pack of cigarettes per day for 35 years; he quit 6 years ago.

127 topically to a designated target lesion once per day for 4 consecutive days on days 1 through 4, 8 th

128 et area under the curve 4000 mumol/L per min per day for 4 days) and melphalan (60 mg/m(2) per day fo

129 etoposide continuous infusion of 338 mg/m(2) per day for 4 days, and melphalan 70 mg/m(2) per day for

130 a concentration-time curve 4.1 mg/mL per min per day for 4 days, etoposide continuous infusion of 338

131 ovir alafenamide 10 mg, which was taken once per day for 48 weeks.

132 ents after RIC with fludarabine of 100 mg/kg per day for 5 days, cyclophosphamide of 60 mg/kg per day

133 etrozole (2.5 mg) or anastrozole (1 mg) once per day for 5 years or until recurrence of disease.

134 icillin and 500 mg metronidazole three times per day for 7 days during the non-surgical treatment pha

135 e placebo or hydrocortisone (0.5 mg/kg twice per day for 7 days, followed by 0.5 mg/kg per day for 3

136 ked binge-like eating in rats responding 1 h per day for a highly palatable sugary diet.

137 iations were among persons taking >1.5 pills per day for at least 10 years (odds ratio, 4.27; 95% CI,

138 reatment with oral rucaparib at 600 mg twice per day for continuous 28 day cycles until disease progr

139 defined by WHO as three or more loose stools per day for less than 14 days).

140 rombopag or placebo at 100 mg per day (50 mg per day for patients of east-Asian heritage) to a maximu

141 tage) to a maximum of 300 mg per day (150 mg per day for patients of east-Asian heritage).

142 At week 12, mean BM frequency reductions per day for placebo, telotristat ethyl 250 mg, and telot

143 dressed with gauze with 0.5% PVI for 1 hour per day for the first 5 days after injury.

144 ister palatable food pellets for 6 days (6 h per day) for either methamphetamine (0.1 mg/kg/infusion)

145 33 and 129.44 (per 1 million persons at risk per day) for the entire year and for the warm season, re

146 s or to intravenous bendamustine (90 mg/m(2) per day) for the first 2 days of each cycle.

147 ) per day) and cyclophosphamide (250 mg/m(2) per day) for the first 3 days or to intravenous bendamus

148 per week or oral bexarotene 300 mg/m(2) once per day) for up to 48 weeks.

149 00 mg per day for 3 days, followed by 400 mg per day, for 11 days; thereafter, all the patients recei

150 fedratinib at a starting dose of 400 mg once per day, for six consecutive 28-day cycles.

151 In control pups, separated for 15 minutes per day, gamma power had highly significant correlations

152 15, every 4 weeks plus erlotinib 100 mg once per day (GemErlo) or gemcitabine (Gem) alone for six cyc

153 Dose escalation ceased at 160 mg per day given lack of MTD and endoxifen concentrations >

154 live oil as vehicle), group B (CsA, 30 mg/kg per day), group C (CsA + Val, 30 + 30 mg/kg per day), an

155 Group 1 received >/=0.2 mg/kg per day, group 2 cycled on/off NTBC (0.05 mg/kg per day

156 ients who consumed at least 4 cups of coffee per day had a 52% lower risk of CRC-specific death (haza

157 oking and other potential confounders (1 cup per day: hazard ratio [HR], 0.88 [95% CI, 0.85 to 0.91];

158 day: HR, 0.82 [CI, 0.79 to 0.86]; >/=4 cups per day: HR, 0.82 [CI, 0.78 to 0.87]; P for trend < 0.00

159 R], 0.88 [95% CI, 0.85 to 0.91]; 2 to 3 cups per day: HR, 0.82 [CI, 0.79 to 0.86]; >/=4 cups per day:

160 In wild-type (WT) mice, LY2828360 (3 mg/kg per day i.p. x 12 days) suppressed chemotherapy-induced

161 Morphine (10 mg/kg per day i.p. x 12 days) tolerance developed in CB2KO mic

162 Coadministration of LY2828360 (0.1 mg/kg per day i.p. x 12 days) with morphine (10 mg/kg per day

163 usly rendered tolerant to morphine (10 mg/kg per day i.p. x 12 days), but it was absent in morphine-t

164 th a history of LY2828360 treatment (3 mg/kg per day i.p. x 12 days).

165 d 1-3 y and the number of potential servings per day ([i.e., 1500 mg/7 servings (>210 mg/RACC)], a so

166 e the target of an intake of 8 cups of water per day in adolescents.

167 he testes, producing millions of spermatozoa per day in an adult male in rodents and humans.

168 by urinary excretion of 174+/-64 mmol Na(+) per day in the combined RS groups and 108+/-61 mmol Na(+

169 havioral supports to consume 8 cups of water per day in the context of a weight-reducing diet did not

170 completed a similar number of foraging bouts per day in the field.

171 e combined RS groups and 108+/-61 mmol Na(+) per day in the LS groups (P<0.001).

172 hypotension episode (median of 2.5 episodes per day in this subgroup).

173 e and centre) to receive olesoxime (10 mg/kg per day) in an oral liquid suspension or placebo for 24

174 we investigated the effects of PYR (40 mg/kg per day) in experimental PH.

175 ice per day) plus oral trametinib (2 mg once per day) in four patient cohorts with melanoma brain met

176 cyclohexandione (NTBC) at a dose of 1 mg/kg per day initially after birth.

177 poverty lines: the US$1.90 per day and $3.10 per day international poverty lines and a relative pover

178 onist/antagonist pimavanserin (0.32-10 mg/kg per day, intramuscular) attenuated cocaine reinforcement

179 the 5-HT2C agonist lorcaserin (0.1-1.0 mg/kg per day, intramuscular; 0.032-0.1 mg/kg/h, intravenous)

180 enously on day 1] and fluorouracil [1 g/m(2) per day intravenously on days 1-4]) or four cycles of ep

181 2.3-4.4; p<0.0001] in the lumacaftor [600 mg per day]-ivacaftor group and 2.8 percentage points [1.7-

182 nary artery disease (CAD), cigarettes smoked per day, lung cancer, insulin resistance and body fat ar

183 ed individual passing up to 45 million cysts per day, making cyst production an attractive target for

184 Mice received tacrolimus (FK-506, 0.1 mg/kg per day)/mycophenolate mofetil (MMF, 60 mg/kg per day),

185 ere randomly assigned to enzalutamide 160 mg per day (n = 198) or bicalutamide 50 mg per day (n = 198

186 0 mg per day (n = 198) or bicalutamide 50 mg per day (n = 198).

187 a binocular iPad game prescribed for 1 hour per day (n = 40) or patching of the fellow eye prescribe

188 ing of the fellow eye prescribed for 2 hours per day (n = 60).

189 nsisting of the ingestion of one chicken egg per day; no allergic symptoms have been observed during

190 king and vaping (number of cigarettes smoked per day, number of vaping episodes per day, and number o

191 rval, 1.03 to 2.51 for one or two injections per day; odds ratio, 1.88; 95% confidence interval, 1.30

192 ence interval, 1.30 to 3.43 for 3 injections per day; odds ratio, 3.74; 95% confidence interval, 2.28

193 y still had doses equivalent to five tablets per day of 5-mg hydrocodone.

194 users ( P = .05), equivalent to six tablets per day of 5-mg hydrocodone.

195 solute increase of pneumonia incidence of 1% per day of delay.

196 y translated into standard drink equivalents per day of different countries, the WHO risk levels coul

197 the patients still have more than 1.5 hours per day of off time.

198 of CsA and/or Val: group A (control, 1 mL/kg per day of olive oil as vehicle), group B (CsA, 30 mg/kg

199 A total of 11 volunteers consumed 10 g per day of three types of seaweeds (nori, kombu, and wak

200 mponents (0.60), early use of rifampin (0.98 per day of treatment within the first 30 days), and long

201 ed 13 person-hours of contact and 8 contacts per day on average, which decreased over age but increas

202 nts received either ATLG or placebo 20 mg/kg per day on days -3, -2, -1 in addition to tacrolimus and

203 curve 5 on day 1 plus etoposide 100 mg/m(2) per day on days 1 to 3 every 21 days (CE) or carboplatin

204 /m(2) per day plus palifosfamide 130 mg/m(2) per day on days 1 to 3 every 21 days (PaCE).

205 enous fluorouracil (one dose of 1000 mg/m(2) per day on days 1-4 and 29-32) and radiotherapy (50.4 Gy

206 in (either 80 mg/m(2) on day 1 or 20 mg/m(2) per day on days 1-4 of radiotherapy at clinician's discr

207 on) and intravenous fluorouracil 800 mg/m(2) per day on days 1-4 of radiotherapy in week 1.

208 utuximab (17.5 mg/m(2) per day or 25 mg/m(2) per day) on days 2-5 plus granulocyte macrophage colony-

209 ogression, and either oral vandetanib 300 mg per day once daily or matching placebo.

210 ceived intravenous dinutuximab (17.5 mg/m(2) per day or 25 mg/m(2) per day) on days 2-5 plus granuloc

211 nd from physicians who saw 25 to 44 patients per day or 45 or more patients per day than those who sa

212 a dose of 60 mg per kilogram of body weight per day or a control (soy) emulsion without DHA until 36

213 hat was adjusted to a maximum dose of 600 mg per day or matching placebo for up to 8 weeks.

214 a dose of 20 mg per kilogram of body weight per day or placebo, in addition to standard antiepilepti

215 e of six) to receive oral buparlisib (100 mg per day) or matching placebo starting on day 1 of cycle

216 ataluren orally three times daily (40 mg/kg per day) or matching placebo.

217 ardiovascular disease to rosuvastatin (10 mg per day) or placebo and to candesartan (16 mg per day) p

218 injections) to receive sotagliflozin (400 mg per day) or placebo for 24 weeks.

219 randomized double-blind verucerfont (350 mg per day) or placebo for 3 weeks.

220 nse system to receive oral everolimus (10 mg per day) or placebo, both with best supportive care, wit

221 g per day) plus hydrochlorothiazide (12.5 mg per day) or placebo.

222 ere randomly assigned to doxycycline (200 mg per day) or prednisolone (0.5 mg/kg per day) using rando

223 prazine (3 mg, 4.5 mg [target dose], or 6 mg per day) or risperidone (3 mg, 4 mg [target dose], or 6

224 one-to-one ratio to cabozantinib (60 mg once per day) or sunitinib (50 mg once per day; 4 weeks on, 2

225 After 4 wk of oral CRMP (2 mg/kg body weight per day) or vehicle treatment, mice underwent hyperinsul

226 of 0.7 to 1.0 mg per kilogram of body weight per day, or itraconazole capsules (221 patients), at a d

227 psia to receive aspirin, at a dose of 150 mg per day, or placebo from 11 to 14 weeks of gestation unt

228 mg, or telotristat ethyl 500 mg three times per day orally during a 12-week double-blind treatment p

229 eived open-label, BIIB074 150 mg three times per day, orally, for 21 days.

230 rom 3 mg per day to the target dose of 12 mg per day over 12 weeks.

231 1) to receive either oral masitinib (6 mg/kg per day over 24 weeks with possible extension) or matche

232 emether and 120 mg lumefantrine, given twice per day over 3 days for a total of six doses) to elimina

233 und NC membrane was used maximally 8-9 times per day over a period of 180 days, when stored in 0.01M

234 rrelated with an additional diarrheal motion per day (P = .008).

235 x-smokers and current smokers for cigarettes per day (P for interactionex = 6.0 x 10(-8); P for inter

236 ween whole-brain SUV and reported cigarettes per day (P<0.05), but no significant relationship was fo

237 mean daily bolus dose of insulin (-2.8 units per day) (P</=0.002 for all comparisons).

238 s, 1.6 cups per day [95% CI, 0.2 to 3.0 cups per day]; P = .03).

239 smoking status, smoking duration, cigarettes per day, pack-years smoked, time since smoking cessation

240 In three randomly prompted entries (RPs) per day, participants reported the severity of stress an

241 otentially, targets will be consumed at 1 M per day per reactor, demanding a 5000x unit cost reducti

242 Patients received selumetinib 100 mg orally per day plus MK-2206 135 mg orally once per week or mFOL

243 tients received oral dabrafenib 150 mg twice per day plus oral trametinib 2 mg once per day until dis

244 curve 4 on day 1 plus etoposide 100 mg/m(2) per day plus palifosfamide 130 mg/m(2) per day on days 1

245 er day) or placebo and to candesartan (16 mg per day) plus hydrochlorothiazide (12.5 mg per day) or p

246 tudy evaluated oral dabrafenib (150 mg twice per day) plus oral trametinib (2 mg once per day) in fou

247 opinavir 400 mg with ritonavir 100 mg, twice per day) plus two or three clinician-selected NRTIs (pro

248 sample are cent1.22 per capita at the $1.90 per day poverty line and cent3.74 per capita at the $3.1

249 e of impoverishment is negative at the $1.90 per day poverty line but positive at the $3.10 per day a

250 We estimate that at the $1.90 per day poverty line, the worldwide incidence of impover

251 ty line and cent3.74 per capita at the $3.10 per day poverty line.

252 speridone (3 mg, 4 mg [target dose], or 6 mg per day); previous medication was discontinued over 2 we

253 At a threshold of >/=5 points, per day probability of VRE BSI was increased nearly 4-fo

254 ase inhibitor plus raltegravir (400 mg twice per day; protease inhibitor plus raltegravir group), or

255 ce annual average POAI by up to 1.5 kWh/m(2) per day relative to pollution-free conditions, a decreas

256 The average number of cigarettes per day reported by the mothers who were smoking during

257 f 70-180 mg/dL (3.9-10.0 mmol/L) was 791 min per day (SD 157) in the CGM plus CSII group and 741 min

258 measured, and the animals underwent 2 scans per day separated by about 4 h.

259 ation of airflow obstruction with cigarettes per day, smoking duration, and pack-years did not follow

260 agnitude counts per minute (VM CPM) and time per day spent in different PA intensity levels were defi

261 ingested dry powder of raw egg-white 5 times per day starting with a tenth of the threshold dose (3.0

262 2.28 to 6.25 for more than three injections per day), suggesting a dose-effect relationship between

263 o 44 patients per day or 45 or more patients per day than those who saw fewer than 25 patients per da

264 eceive either pregabalin at a dose of 150 mg per day that was adjusted to a maximum dose of 600 mg pe

265 To support adherence to 8 cups of water per day, the water group received well-defined messages

266 ed advice to increase water intake to 8 cups per day; the control group did not receive such advice)

267 The starting dose of CPI-613 was 500 mg/m(2) per day; the dose level was then escalated by doubling t

268 -daily insulin glargine (starting dose 10 IU per day, then titrated weekly to a pre-breakfast self-me

269 dose of 10 mg per day for 3 weeks and 20 mg per day thereafter.

270 alytical throughputs from 24 to 1200 samples per day to enable different MS analysis approaches.

271 Rivastigmine was uptitrated from 3 mg per day to the target dose of 12 mg per day over 12 week

272 triptyline (1 mg per kilogram of body weight per day), topiramate (2 mg per kilogram per day), and pl

273 >36% for consumed total carbohydrate (grams per day), total saturated fatty acids (SFAs), percentage

274 Repeated pimavanserin (3.2 mg/kg per day) treatments significantly increased small unit c

275 Patients took 20-240 mg osimertinib per day until disease progression or development of into

276 twice per day plus oral trametinib 2 mg once per day until disease progression, unacceptable adverse

277 to produce the target at roughly 3 kilograms per day using small continuous reactors, extractors, eva

278 (200 mg per day) or prednisolone (0.5 mg/kg per day) using random permuted blocks of randomly varyin

279 esults Estimated differences in BM frequency per day versus placebo averaged over 12 weeks were -0.81

280 -week run-in period receiving one inhalation per day via single-dose dry-powder inhaler of open-label

281 Tadalafil at 5 mg once per day was commenced after 1 week as penile rehabilitat

282 nificantly greater number of vaping episodes per day was found with use of low (adjusted RR, 3.32; 95

283 Engaging in prayer several times per day was not associated with mortality after control

284 24); gamma in pups separated for 180 minutes per day was not correlated with either factor.

285 se 2 study, oral acalabrutinib (100 mg twice per day) was given to patients with relapsed or refracto

286 nalidomide dose escalation (to 5 mg or 10 mg per day) was permitted if the drug was well tolerated.

287 accelerometer units (ADAU) and hours active per day were assessed during a 14-day period before star

288 y 13.4% (95% CI, -16.0% to -10.8%; P < .001) per day when cost sharing was increased in 2012.

289 glucose monitoring goals of 4 or more checks per day with 1 or more level within the goal range (70-1

290 eive (all orally) either 35 mg/kg rifampicin per day with 15-20 mg/kg ethambutol, 20 mg/kg rifampicin

291 ith 400 mg moxifloxacin, 20 mg/kg rifampicin per day with 300 mg SQ109, 10 mg/kg rifampicin per day w

292 r day with 300 mg SQ109, 10 mg/kg rifampicin per day with 300 mg SQ109, or a daily standard control r

293 15-20 mg/kg ethambutol, 20 mg/kg rifampicin per day with 400 mg moxifloxacin, 20 mg/kg rifampicin pe

294 ed at least 1 hour of troublesome dyskinesia per day with at least mild functional impact.

295 ipants received a single-tablet regimen once per day with food (administered by their parent or carer

296 received oral venetoclax, starting at 20 mg per day with stepwise dose ramp-up over 5 weeks to 400 m

297 rapy with concurrent temozolomide 75 mg/m(2) per day, with or without adjuvant temozolomide.

298 day, group 2 cycled on/off NTBC (0.05 mg/kg per day x 1 week/0 mg/kg per day x 3 weeks), and group 3

299 day i.p. x 12 days) with morphine (10 mg/kg per day x 12 days) blocked morphine tolerance in WT but

300 ff NTBC (0.05 mg/kg per day x 1 week/0 mg/kg per day x 3 weeks), and group 3 received no NTBC thereaf